June 2011 Issue
As PTFE diaphragms are subjected to more aggressive sterilization and cooling conditions, they are more prone to failure from cracking, splitting, deformation and SIP steam-induced blisters.
Long-term success in biopharma will hinge on the technical and commercial decisions companies make today.
Tunnell Consultings Carla Reed provides a six-step approach for establishing drug products digital DNA, with an eye towards ROI as well as compliance.
Recent research suggests not, and prompts FDA to clarify its position on the issue.
Reports of the demise of radio frequency identification as a breakthrough supply chain technology have been greatly exaggerated.
Pharma companies got a rude awakening this month as Facebook plans to make it mandatory to allow for user comments.
For an industry rooted in science, why are drug prices set so unscientifically?
Is the greening of pharma merely moss on a stagnant stone?
In biopharma, budgets are returning and manufacturers are emphasizing innovation, productivity, and cost control.
Three-to-four-month flu vaccine manufacturing cycles are within reach.
In this interview, Wessels talks with PharmaManufacturing.com Senior Editor Paul Thomas about why sustainability matters, and how sustainable practices can become part of a drug manufacturers genetic makeup.
A new survey sheds light upon choices and challenges.
A product round-up of valves, pumps and other fluid control devices.